Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Access Program for Psoriasis (PRIDE)
NCT00513370Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2007
- Primary completion
- Sep 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in plaque psoriasis, sponsored by Abbott Laboratories. Primary endpoint: Proportion of Subjects Achieving PASI 75 Response at 16 weeks. Started Sep 2007; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00513370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00513370.